background
clinic
trial
appli
iotacarrageenan
nasal
spray
previous
shown
reduc
durat
virusconfirm
common
cold
present
studi
pool
data
two
similar
clinic
trial
provid
evid
antivir
effect
carrageenan
method
individu
patient
data
analyz
two
random
doubl
blind
placebo
control
trial
assess
therapeut
effect
carrageenan
nasal
spray
acut
common
cold
patient
virusconfirm
common
cold
n
verum
placebo
includ
follow
paramet
apprais
durat
diseas
number
patient
relaps
number
respiratori
virus
viral
titer
inclus
visit
compar
day
visit
result
carrageenan
treat
patient
show
signific
reduct
durat
diseas
almost
day
p
well
significantli
fewer
relaps
day
observ
period
p
viru
clearanc
visit
visit
significantli
pronounc
carrageenan
group
p
studi
virusconfirm
common
cold
caus
three
main
viru
subtyp
human
rhinoviru
human
coronaviru
influenza
viru
carrageenan
nasal
spray
show
signific
antivir
efficaci
three
viru
subgroup
highest
effect
observ
human
corona
virusinfect
patient
reduc
durat
diseas
day
p
number
relaps
three
time
less
p
carrageenan
treat
coronavirusinfect
patient
compar
control
patient
conclus
administr
carrageenan
nasal
spray
children
well
adult
suffer
virusconfirm
common
cold
reduc
durat
diseas
increas
viral
clearanc
reduc
relaps
symptom
carrageenan
nasal
spray
appear
effect
treatment
common
cold
children
adult
trial
registr
pool
data
acut
viral
upper
respiratori
tract
infect
also
known
common
cold
frequent
observ
infecti
diseas
human
be
children
get
four
eight
upper
respiratori
infect
per
year
adult
suffer
two
four
episod
per
year
major
case
common
cold
caus
respiratori
virus
rhinoviru
coronaviru
parainfluenza
influenza
respiratori
syncyti
viru
adenoviru
enteroviru
metapneumoviru
although
common
cold
selflimit
diseas
symptom
runni
nose
nasal
congest
sneez
cough
sore
throat
malais
fever
troublesom
lead
million
doctor
visit
million
lost
school
work
day
per
year
despit
enorm
econom
social
burden
common
cold
effect
treatment
still
avail
common
cold
caus
divers
virus
effect
therapeut
substanc
exhibit
broad
antivir
capac
lead
resist
format
carrageenan
may
repres
option
carrageenan
belong
famili
linear
sulfat
polysaccharid
found
speci
red
seawe
food
cosmet
pharmaceut
industri
use
carrageenan
extens
emulsifi
bind
agent
product
like
ice
cream
variou
gel
toothpast
other
carrageenan
also
reveal
antivir
activ
rang
anim
virus
even
use
prevent
sexual
transmit
viral
infect
compon
spermicid
furthermor
vitro
vivo
studi
recent
shown
carrageenan
potent
inhibitor
papilloma
viru
human
rhinoviru
influenza
viru
respiratori
syncyti
viru
also
human
enteroviru
three
random
control
clinic
trial
rct
show
superior
symptomat
benefit
antivir
efficaci
carrageenan
contain
nasal
spray
patient
common
cold
current
studi
aim
provid
deeper
insight
result
two
larger
rct
carrageenan
larg
polym
permeat
nasal
mucosa
antivir
effect
base
physic
mode
action
therefor
hostindepend
mode
action
allow
pool
data
studi
children
adult
would
accept
substanc
exhibit
pharmacolog
action
subgroup
individu
virus
two
trial
quit
small
pool
data
allow
analysi
subgroup
frequent
occur
virus
addit
investig
broad
antivir
activ
observ
vitro
envelop
virus
influenza
corona
viru
nonenvelop
virus
rhinoviru
also
reflect
clinic
data
therefor
data
two
similar
trial
merg
addit
analysi
regard
antivir
effect
carrageenan
nasal
spray
patient
virusconfirm
common
cold
perform
individu
patient
data
two
phase
iii
random
doubleblind
placebocontrol
trial
pool
analysi
main
characterist
trial
given
tabl
trial
approv
independ
ethic
committe
particip
centr
conduct
accord
declar
helsinki
applic
local
regul
main
inclus
criteria
trial
presenc
earli
symptom
common
cold
symptom
hour
enrol
children
trial
hour
adult
trial
sever
cold
measur
use
symptom
score
score
calcul
sum
symptom
headach
muscl
ach
chilli
sore
throat
nasal
obstruct
nasal
discharg
cough
sneez
item
rate
absent
mild
moder
sever
patient
symptom
score
children
trial
adult
trial
time
inclus
enrol
studi
investig
patient
mask
treatment
test
spray
match
placebo
indistinguish
patient
randomli
assign
use
permut
block
schedul
size
four
random
patient
receiv
treatment
either
iotacarrageenan
nasal
spray
sodium
salin
carrageenan
placebo
sodium
salin
placebo
three
time
per
day
day
presenc
common
cold
symptom
record
daili
diari
till
day
inclus
trial
nasal
lavag
sampl
collect
day
visit
first
applic
medic
either
day
day
respect
visit
treatment
second
trial
nasal
lavag
sampl
also
obtain
studi
day
treatment
one
third
sampl
viru
posit
patient
also
includ
analysi
molecular
screen
quantit
assess
viral
load
nasal
lavag
sampl
perform
influenza
viru
type
infa
b
inf
b
respiratori
syncyti
viru
rsv
parainfluenza
virus
piv
type
human
rhinoviru
hrv
human
metapneumoviru
mpv
coronaviru
type
hcv
patient
consid
virusposit
viru
detect
least
one
sampl
detail
inform
method
use
see
previou
public
accord
studi
object
patient
data
virusposit
patient
includ
pool
analysi
assess
clinic
effect
follow
paramet
determin
durat
diseas
number
frequenc
relaps
durat
diseas
defin
time
last
day
symptom
common
cold
relaps
defin
reoccurr
symptom
patient
report
common
cold
symptom
report
least
one
day
without
symptom
assess
antivir
effect
follow
variabl
select
number
differ
virus
detect
chang
viral
titer
number
patient
virus
similar
advers
event
occur
sever
time
one
patient
sever
common
cold
virus
infect
one
patient
time
consequ
calcul
differ
viral
titer
concept
viru
event
appli
mean
calcul
perform
viru
individu
gender
age
assess
import
demograph
covari
analysi
paramet
perform
virusposit
vp
popul
patient
subgroup
posit
specif
viru
frequent
detect
one
ie
hrv
hcv
infa
find
screen
visit
document
advers
effect
ae
except
symptom
attribut
common
cold
sneez
runni
nose
nasal
obstruct
sore
throat
cough
headach
fatigu
chilli
nevertheless
symptom
mark
intens
deem
relat
studi
diseas
record
ae
statist
analysi
perform
use
statist
ibm
softwar
packag
spss
version
analysi
durat
diseas
done
use
log
rank
test
data
set
check
normal
distribut
kolmogorovsmirnovtest
prior
analysi
binari
categor
data
eg
presenc
absenc
virus
number
patient
advers
event
analys
chisquar
test
viral
titer
nasal
lavag
sampl
chang
viral
titer
visit
analys
use
nonparametr
mannwhitney
utest
due
fact
distribut
data
normal
addit
data
set
highli
skew
dataset
analysi
virus
detect
includ
viru
account
individu
two
doubleblind
random
control
trail
virusposit
patient
enrol
intentiontotreat
itt
popul
patient
random
carrageenan
treatment
wherea
patient
alloc
placebo
treatment
perprotocol
pp
popul
remain
patient
divid
patient
carrageenan
group
patient
placebo
group
figur
demograph
data
shown
tabl
viru
posit
itt
popul
consist
femal
carrageenan
placebo
male
carrageenan
placebo
tabl
statist
signific
differ
recogn
distribut
male
femal
carrageenan
placebo
group
itt
popul
differ
deriv
mainli
studi
undertaken
children
mean
age
year
nevertheless
statist
adjust
analysi
perform
nt
show
differ
result
data
shown
distribut
differ
seen
patient
popul
eg
pp
popul
one
three
viru
infect
subgroup
data
shown
inclus
intens
common
cold
symptom
symptom
score
similar
carrageenan
placebo
treat
patient
itt
popul
p
similarli
differ
pp
popul
respect
group
carrageenan
placebo
durat
common
cold
symptom
significantli
reduc
carrageenan
treat
patient
compar
placebo
treat
one
itt
pp
popul
averag
durat
diseas
diminish
day
itt
carrageenan
group
day
pp
carrageenan
group
compar
respect
placebo
group
itt
p
pp
p
figur
day
observ
relaps
observ
significantli
frequent
placebo
group
carrageenan
treat
patient
irrespect
itt
pp
popul
itt
p
pp
p
figur
patient
one
relaps
observ
period
averag
number
relaps
per
patient
calcul
averag
number
relaps
per
patient
carrageenan
treat
patient
compar
placebo
treat
patient
itt
popul
p
likewis
averag
number
relaps
per
patient
significantli
higher
placebo
group
name
compar
carrageenan
group
pp
popul
observ
period
p
analysi
antivir
effect
patient
virusposit
visit
day
visit
day
visit
includ
patient
miss
visit
exclud
analysi
incomplet
data
tabl
sinc
patient
one
viru
detect
treatment
group
compar
regard
number
virus
per
patient
visit
wherea
baselin
group
differ
significantli
visit
number
virus
per
patient
significantli
lower
carrageenan
group
accordingli
chang
number
virus
per
patient
visit
visit
pronounc
carrageenan
group
averag
placebo
patient
clear
virus
carrageenan
treat
patient
lost
virus
itt
popul
p
similarli
pp
popul
viru
clearanc
placebo
group
versu
carrageenan
group
p
carrageenan
treat
patient
signific
increas
virusfre
patient
observ
visit
visit
itt
well
pp
popul
contrast
placebo
treat
patient
show
differ
virusfre
individu
visit
visit
tabl
figur
show
percentag
patient
either
deterior
defin
increas
viral
titer
visit
detect
new
viru
reveal
visit
improv
defin
decreas
viral
titer
visit
elimin
viru
present
visit
chang
defin
viral
titer
visit
compar
visit
viru
statu
visit
visit
significantli
patient
reveal
improv
viral
statu
visit
visit
carrageenan
treat
patient
compar
placebo
treat
one
itt
well
pp
popul
itt
p
pp
p
figur
two
pool
studi
follow
virus
detect
frequent
hrv
patient
hcv
type
patient
infa
patient
patient
posit
differ
viral
type
distribut
evenli
carrageenan
placebo
treatment
arm
tabl
subgroup
analysi
done
three
common
viru
type
pool
popul
hrv
hcv
infa
viru
respect
itt
popul
durat
common
cold
diseas
significantli
reduc
three
viru
subgroup
treat
carrageenan
effect
pronounc
hcv
infect
patient
treat
carrageenan
reduct
durat
almost
day
itt
popul
p
day
pp
popul
p
tabl
figur
three
viru
subgroup
signific
reduct
durat
common
cold
record
carrageenan
treat
patient
compar
placebo
one
itt
popul
similarli
signific
reduct
seen
pp
popul
carrageenan
placebo
group
except
infa
patient
relaps
occur
significantli
frequent
placebo
group
hrv
hcv
infect
patient
compar
carrageenan
group
itt
popul
similarli
infa
infect
patient
trend
relaps
observ
placebo
group
p
figur
also
pp
popul
higher
percentag
relaps
notic
placebo
treat
viru
infect
subgroup
howev
hcv
infect
patient
differ
reach
statist
signific
p
figur
itt
popul
averag
number
relaps
per
patient
significantli
lower
carrageenan
treat
virusinfect
subgroup
thu
hrv
infect
patient
averag
number
relaps
per
patient
carrageenan
treat
patient
placebo
treat
one
p
hcv
infect
patient
relaps
per
patient
occur
time
carrageenan
treat
patient
compar
time
placebo
treat
one
p
moreov
placebo
treat
infa
infect
patient
relaps
per
patient
compar
relaps
per
patient
carrageenan
group
p
likewis
total
relaps
pp
popul
higher
averag
number
relaps
per
patient
recogn
viru
infect
subgroup
sole
hcv
infect
subpopul
differ
reach
signific
versu
p
overal
toler
studi
product
good
differ
treatment
arm
number
patient
ae
sever
advers
event
sae
tabl
patient
report
ae
end
observ
period
interestingli
rhiniti
newli
diagnos
case
deterior
condit
studi
observ
frequent
placebo
group
case
carrageenan
treatment
arm
compar
case
placebo
statist
signific
differ
group
p
two
studi
six
patient
experienc
sae
none
studi
relat
sae
resolv
end
studi
ae
rate
notstudyrel
present
studi
data
two
random
control
clinic
trial
investig
effect
carrageenan
nasal
spray
virusconfirm
common
cold
analyz
analysi
show
carrageenancontain
nasal
spray
reduc
durat
viralconfirm
common
cold
almost
day
furthermor
carrageenantr
patient
clear
twice
mani
virus
compar
placebotr
patient
addit
virusfre
patient
found
carrageenantr
patient
visit
anoth
clinic
benefit
carrageenan
nasal
spray
signific
reduct
relaps
defin
recurr
symptom
patient
free
symptom
least
one
day
annual
common
cold
account
million
doctor
visit
million
lost
school
work
day
usa
alon
frequent
observ
infecti
diseas
human
be
four
eight
episod
per
year
children
three
five
adult
therefor
reduct
diseas
durat
day
enorm
impact
econom
loss
social
welfar
children
famili
common
cold
mainli
caus
respiratori
virus
human
rhinoviru
human
coronaviru
parainfluenza
influenza
respiratori
syncyti
viru
adenoviru
enteroviru
metapneumoviru
sinc
imposs
individu
determin
caus
cold
import
know
product
use
provid
effect
mani
differ
respiratori
virus
caus
cold
present
studi
analysi
viru
speci
reveal
human
rhinoviru
human
coronaviru
influenza
viru
common
speci
nasal
administr
carrageenan
common
cold
episod
consist
show
reduct
durat
diseas
patient
subgroup
infect
three
virus
decreas
durat
diseas
vari
day
rhinoviru
day
coronaviru
infa
lie
reduct
day
tabl
studi
data
suggest
carrageenan
nasal
spray
exert
unspecif
effect
virus
differ
etiolog
origin
envelop
nonenvelop
virus
experiment
data
support
notion
show
carrageenan
exhibit
potent
inhibitori
effect
papilloma
viru
moreov
vitro
vivo
studi
reveal
carrageenan
effect
sever
human
respiratori
virus
influenza
human
rhinoviru
respiratori
syncyti
viru
also
human
enteroviru
shown
carrageenan
polym
directli
bound
viru
prevent
attach
viru
cell
henc
carrageenan
work
via
unspecif
physic
mode
action
earli
stage
viru
life
cycl
see
figur
previou
page
figur
percentag
patient
dynam
chang
viral
statu
visit
visit
deterior
defin
increas
viral
titer
visit
detect
new
viru
reveal
visit
improv
defin
decreas
viral
titer
visit
elimin
viru
present
visit
chang
defin
viral
titer
visit
compar
visit
itt
popul
p
b
pp
popul
p
common
cold
benign
selflimit
diseas
decreas
viral
titer
visit
visit
carrageenantr
placebotr
patient
expect
carrageenantr
patient
clear
twice
mani
virus
compar
placebotr
patient
lead
virusfre
patient
visit
carrageenan
group
tabl
conclud
treatment
iotacarrageenan
result
signific
reduct
viral
load
number
detect
virus
alreadi
day
absenc
virus
lead
faster
recoveri
henc
earlier
clearanc
symptom
data
line
result
current
avail
clinic
trial
regard
iotacarrageenantreat
common
cold
benefit
carrageenan
treatment
signific
reduct
relaps
defin
recurr
symptom
patient
free
symptom
least
one
day
figur
relaps
took
place
cessat
treatment
prophylact
effect
carrageenan
nasal
spray
could
hypothes
similarli
viru
posit
patient
relaps
reduc
carrageenan
nasal
spray
three
virusinfect
patient
subgroup
patient
infect
human
coronaviru
benefit
carrageenan
treatment
show
reduct
relaps
compar
placebo
figur
human
rhinoviru
infect
patient
well
influenza
infect
patient
reveal
twofold
reduct
relaps
treat
carrageenan
nasal
spray
reduct
relaps
reduct
viru
titer
carrageenan
treat
patient
might
interest
particular
patient
subgroup
underli
diseas
asthma
copd
numer
recent
review
discuss
presenc
respiratori
virus
caus
exacerb
asthma
copd
acut
exacerb
associ
decreas
lung
growth
children
acceler
loss
lung
function
add
substanti
cost
morbid
associ
asthma
therefor
reduct
viru
load
persist
benefici
effect
patient
especi
children
frequent
suffer
viral
infect
often
involv
one
viru
could
benefit
carrageenan
nasal
spray
due
physic
mode
action
favor
side
effect
profil
could
use
costeffect
long
time
prevent
measur
cost
treatment
lie
one
dollar
per
day
clinic
studi
done
investig
prophylact
effect
carrageenan
nasal
spray
patient
respiratori
diseas
well
patient
group
prevent
viral
infect
utmost
import
eg
cancer
patient
immunocompromis
patient
limit
studi
includ
retrospect
natur
data
analysi
addit
clinic
inform
patient
would
necessari
underlin
find
furthermor
clinic
benefit
use
carrageenan
nasal
measur
eg
spirometri
howev
small
children
includ
data
set
alway
possibl
perform
spirometr
measur
conclus
nasal
applic
carrageenan
spray
children
well
adult
suffer
virusconfirm
common
cold
reduc
durat
diseas
increas
viral
clearanc
reduc
relaps
therefor
carrageenan
nasal
spray
regard
safe
effect
treatment
high
potenti
reduc
social
econom
burden
caus
common
cold
